Endocrine Physiology

Overview & definition

The endocrine physiology — the hypothalamic-pituitary axes (the master regulator). The feedback loops (the negative — the end-product inhibits the upstream). The adrenal, the thyroid, the pancreas (the glucose), the parathyroid (the calcium). The clinical correlations (the thyroid storm, the adrenal crisis, the DKA, the SIADH).[1]

Endocrine physiology matters in the ICU because critical illness is, in part, an endocrine event. Sepsis, trauma, burns and surgery are read by the hypothalamus as existential threats and re-programme every endocrine axis: cortisol and catecholamines rise to defend blood pressure, glucagon and counter-regulatory hormones drive stress hyperglycaemia, antidiuretic hormone retains water even at the cost of hyponatraemia, and thyroid hormone activation is deliberately switched off to conserve energy. The intensivist who understands these axes can distinguish an ADAPTIVE response (sick euthyroidism, stress hyperglycaemia) from a DEFICIENT one (critical illness-related corticosteroid insufficiency, relative vasopressin deficiency) — and treat only the latter.[5][9]

The axes

• The HPA (the hypothalamic-pituitary-adrenal): CRH → ACTH → cortisol (the negative the feedback). The cortisol (the stress the response; the - the - the).[1]
• The HPT (the hypothalamic-pituitary-thyroid): TRH → TSH → T3/T4 (the negative the feedback). The T4 (the - the - the); the T3 (the active; the - the - the).[1]
• The HPG (the hypothalamic-pituitary-gonadal): GnRH → LH/FSH → the testosterone/oestrogen.[1]
• The GH (the growth hormone) — the GHRH → GH → the IGF-1.[1]
• The prolactin — the - the - the (the dopamine the inhibits).[1]

Hypothalamic-pituitary axis — the master regulator

The hypothalamus is the central coordinator of the endocrine system. Neurosecretory cells in the paraventricular nucleus (and other hypothalamic nuclei) synthesise releasing and inhibiting hormones that travel via the hypophyseal portal venous system — a capillary bed at the median eminence that drains into a second capillary bed in the anterior pituitary. This portal arrangement delivers a high local concentration of hypothalamic hormones to the anterior pituitary while using very little total hormone — a feature that makes the axis both exquisitely sensitive and difficult to study with peripheral blood tests.[1]

The pituitary has two embryologically and functionally distinct parts. The anterior pituitary (adenohypophysis) arises from Rathke's pouch (oral ectoderm) and is a true endocrine gland whose cells synthesise and store hormones under hypothalamic control. The posterior pituitary (neurohypophysis) is a down-growth of neural tissue; it does not synthesise hormones but stores and releases oxytocin and vasopressin (ADH) made in hypothalamic neurons and transported down axons to terminal swellings (Herring bodies).[1]

[1]

Three structural features recur across the axes and are favourite exam points: [1]

1. Negative feedback is the rule — the end-product of each axis inhibits both the hypothalamus and the anterior pituitary. This is why exogenous glucocorticoids suppress the HPA axis (and why abrupt withdrawal causes adrenal crisis), and why exogenous thyroid hormone suppresses TSH.
2. Prolactin is the exception — it is under TONIC DOPAMINERGIC INHIBITION rather than product-mediated negative feedback. Dopamine antagonists (antipsychotics, metoclopramide) raise prolactin; dopamine agonists (cabergoline, bromocriptine) lower it. There is no recognised hypothalamic prolactin-releasing hormone of equivalent importance.
3. Pulsatility matters — GnRH must be delivered in pulses to maintain gonadotroph responsiveness; a continuous GnRH analogue (leuprorelin, goserelin) paradoxically SUPPRESSES the gonadal axis by downregulating gonadotroph receptors. This underlies medical androgen-deprivation therapy in prostate cancer. [1]

[1]

Thyroid axis — TRH → TSH → T3/T4

The thyroid follicle is the structural unit: a sphere of follicular cells surrounding a central colloid lake filled with thyroglobulin. Thyroid hormone synthesis is unique in endocrinology because it couples an inorganic substrate (iodide) to an organic backbone (tyrosine) on a stored protein, and the whole process is rate-limited by iodide availability. [1]

[1]

The single most important concept is that the thyroid secretes mainly T4 — a prohormone — and that ~80% of circulating active T3 is generated peripherally by deiodination. T3 is roughly 4-5 times more biologically active than T4 and is the principal ligand for the nuclear thyroid hormone receptor, which acts as a ligand-gated transcription factor controlling basal metabolic rate, thermogenesis, Na/K-ATPase activity, cardiac beta-adrenergic receptor density and skeletal growth.[2]

[1]

Adrenal axis — CRH → ACTH → cortisol

The adrenal cortex has three concentric zones, remembered by "GFR — salt, sugar, sex; the deeper you go, the sweeter it gets": the outer zona glomerulosa makes the mineralocorticoid aldosterone (salt); the middle zona fasciculata makes the glucocorticoid cortisol (sugar); the inner zona reticularis makes the androgens DHEA and androstenedione (sex). The medulla, derived from neural crest, is a modified sympathetic ganglion that synthesises and stores catecholamines.[1]

[1] [1]

The catecholamines complete the adrenal stress response. Preganglionic sympathetic fibres synapse on chromaffin cells of the adrenal medulla, which release a ~4:1 mixture of adrenaline and noradrenaline (and a small amount of dopamine) into the bloodstream. Tyrosine → DOPA (tyrosine hydroxylase, rate-limiting) → dopamine → noradrenaline → adrenaline (catalysed by PNMT, induced by cortisol — one reason the cortex and medulla sit together). Catecholamines act within seconds via G-protein-coupled adrenergic receptors: beta-1 (heart — chronotropy, inotropy, renin release), beta-2 (bronchodilation, vasodilation, gluconeogenesis, insulin/glucagon modulation), alpha-1 (vasoconstriction) and alpha-2 (presynaptic autoregulation, inhibition of insulin release).[5]

Stress response — the integrated endocrine reaction to critical illness

Critical illness triggers a coordinated neuroendocrine cascade whose purpose is to maintain perfusion, circulating volume and substrate (glucose, free fatty acids) delivery to vital organs while the body fights, bleeds or heals. The response has two temporal phases. The acute phase (hours to days) is dominated by the sympathetic nervous system and the hypothalamic-pituitary axes: catecholamines, cortisol, ADH, aldosterone and glucagon all rise. This phase is CATABOLIC by design — glycogen, fat and protein are broken down to fuel the response. The chronic phase (weeks), seen in prolonged ICU stay, becomes maladaptive: anterior pituitary secretion becomes pulsatile and disordered, peripheral hormone activation falls (low T3, low IGF-1), and sustained catabolism produces ICU-acquired weakness, hyperglycaemia and immunosuppression.[5][9]

The hormonal players divide into three functional groups: [1]

1. Haemodynamic / volume-maintaining: cortisol (permissive for catecholamines), catecholamines, ADH/vasopressin, and the RAAS (angiotensin II, aldosterone).
2. Substrate-mobilising (counter-regulatory): cortisol, glucagon, catecholamines, growth hormone — all OPPOSE insulin to raise glucose and free fatty acids.
3. Immune-modulating: cortisol (anti-inflammatory) balanced against pro-inflammatory cytokines (IL-1, IL-6, TNF-alpha), which both drive the stress response and induce hormone resistance. [1]

[1]

Critical illness-related corticosteroid insufficiency (CIRCI)

CIRCI — the term coined by the 2008 international consensus task force — is the HPA axis dysfunction that develops DURING critical illness.[1] It differs from classical (Addisonian) adrenal insufficiency in three ways: (1) it is relative — cortisol production is inadequate FOR THE DEGREE OF STRESS, not absolutely absent; (2) it combines adrenal insufficiency with tissue glucocorticoid resistance (cytokines downregulate and impair the glucocorticoid receptor, so even normal cortisol concentrations are functionally inadequate); and (3) it is transient, resolving as the critical illness resolves.[5]

[1]

When to suspect CIRCI: a patient in septic shock who requires escalating or high-dose vasopressors (noradrenaline over about 0.25 mcg/kg/min) despite adequate fluid resuscitation. The 2008 consensus and the Surviving Sepsis Campaign do NOT recommend a random cortisol level or an ACTH stimulation test to DECIDE whether to treat septic shock — the diagnosis is CLINICAL and treatment is empirical hydrocortisone 200 mg/day (50 mg IV 6-hourly or continuous infusion). The classic thresholds (random cortisol under 276 nmol/L, or delta cortisol under 250 nmol/L after 250 mcg ACTH) remain worth knowing as physiology but are not used as treatment gates. Dexamethasone is NOT recommended — it lacks mineralocorticoid activity and suppresses the axis; hydrocortisone must be WEANED, never stopped abruptly, to avoid rebound shock.[1]

Glucose homeostasis — insulin, glucagon and the counter-regulatory hormones

The glucose homeostasis

• The insulin (the beta cell; the - the - the).[1]
• The glucagon (the alpha cell; the - the - the).[1]
• The counter-regulatory (the cortisol, the adrenaline, the GH).[1]

Blood glucose is held within a narrow window (about 4-7 mmol/L) by the balance of insulin (the only hormone that LOWERS glucose) against a redundant set of counter-regulatory hormones that RAISE it (glucagon, adrenaline, noradrenaline, cortisol, growth hormone). The redundancy on the raising side reflects the evolutionary primacy of avoiding hypoglycaemia — the brain is obligately glucose-dependent and cannot tolerate fuel shortage, so multiple hormones back each other up. Insulin stands alone on the lowering side, which is why beta-cell failure (type 1 diabetes) and insulin resistance (type 2, stress) produce hyperglycaemia so readily. [1]

Insulin is synthesised in beta cells of the pancreatic islets as preproinsulin → proinsulin → insulin + C-peptide. Release is triggered by glucose entering beta cells via GLUT2, being phosphorylated by glucokinase (the beta-cell glucose sensor), and raising intracellular ATP, which closes ATP-sensitive K+ channels → depolarisation → voltage-gated calcium influx → exocytosis of insulin granules (the target of sulphonylureas, which directly close K-ATP). Insulin acts via the insulin receptor (receptor tyrosine kinase → IRS-1/PI3K/Akt) to: translocate GLUT4 to skeletal muscle and adipose membranes (glucose uptake); stimulate glycogen synthesis (glycogen synthase); stimulate lipogenesis and inhibit lipolysis; and stimulate protein synthesis. C-peptide is secreted in equimolar amounts with insulin and is the marker used to distinguish endogenous from exogenous insulin.[9]

Glucagon, from alpha cells, is the principal counter-regulatory hormone: it activates hepatic glycogen phosphorylase (via cAMP/PKA) to drive glycogenolysis and induces gluconeogenesis, raising glucose within minutes. The other counter-regulatory hormones — adrenaline, cortisol, growth hormone — act more slowly and on a longer time base but converge on the same hepatic gluconeogenic and glycogenolytic enzymes. They also all induce peripheral insulin resistance, ensuring glucose is diverted away from muscle/fat toward the brain.[9]

[1]

The pivotal clinical lesson is the MANAGEMENT of stress hyperglycaemia. In 2001, van den Berghe's Leuven trial suggested that TIGHT glycaemic control (80-110 mg/dL; 4.4-6.1 mmol/L) dramatically reduced mortality in surgical ICU patients.[4] In 2009 the multinational NICE-SUGAR trial (6104 patients) REVERSED this conclusion: intensive control INCREASED 90-day mortality (27.5% vs 24.9%) driven by a 6-fold increase in severe hypoglycaemia (glucose under 2.2 mmol/L).[3] Modern practice targets 8-10 mmol/L and prioritises HYPOGLYCAEMIA AVOIDANCE, because a single severe hypoglycaemic event is independently associated with death.[6]

Sick euthyroid syndrome (nonthyroidal illness syndrome)

In critical illness the peripheral activation of thyroid hormone is REPROGRAMMED in what is called the sick euthyroid syndrome or nonthyroidal illness syndrome.[2] The pattern is an adaptive, energy-conserving down-tuning of thyroid hormone action:

• T3 FALLS (low T3 syndrome) — 5'-deiodinase activity (D1/D2) is suppressed by cytokines, cortisol and drugs, while the inactivating enzyme D3 is induced, SHUNTING T4 away from active T3 and toward inactive reverse T3.
• Reverse T3 RISES — the inactive metabolite accumulates.
• T4 is normal or low — in prolonged critical illness T4 also falls ("low T4 syndrome").
• TSH is normal or LOW — distinguishing it from primary hypothyroidism, where TSH is HIGH. [1]

This is an ADAPTIVE response: by lowering active T3, the body reduces basal metabolic rate, oxygen consumption and catabolism, conserving energy during the crisis. The clinical error to avoid is treating these abnormal thyroid function tests with levothyroxine — multiple studies show NO benefit (and potential harm). Levothyroxine is indicated ONLY if intrinsic thyroid disease coexists (known Hashimoto's, post-thyroidectomy, amiodarone-induced destructive thyroiditis), recognised by a genuinely ELEVATED TSH.[2]

[1]

Vasopressin physiology and deficiency in shock

Antidiuretic hormone (ADH, also arginine vasopressin) is synthesised in the supraoptic and paraventricular nuclei of the hypothalamus and released from the posterior pituitary. It has two distinct regulatory inputs that compete for control of its release, and understanding which dominates is the key to ICU sodium and water physiology. [1]

• OSMOTIC regulation (the dominant day-to-day control): hypothalamic osmoreceptors detect plasma osmolality with extraordinary sensitivity. ADH release begins at about 280 mOsm/kg and rises steeply to about 295 mOsm/kg, at which point thirst is also triggered. ADH acts on V2 receptors in the renal collecting duct → inserts aquaporin-2 water channels → water reabsorption → concentrates urine and dilutes plasma back toward normal. A slightly high sodium (hypertonicity) is therefore the most powerful stimulus to ADH.
• BARORECEPTOR (non-osmotic) regulation: carotid sinus and aortic arch baroreceptors sense arterial stretch. A FALL in blood pressure or effective circulating volume (over about 10%) is a powerful stimulus to ADH release EVEN IF plasma osmolality is low. This is the "non-osmotic ADH release" of shock, heart failure and cirrhosis: the body sacrifices osmolality to preserve circulating volume. ADH also acts on V1a receptors on vascular smooth muscle → vasoconstriction → a pressor effect exploited therapeutically in vasoplegic shock. [1]

[1] [1]

Sodium and water balance — ADH, V2 receptors and the RAAS

Sodium and water are regulated in tandem but by partly separable systems. Water balance is governed by ADH (V2/aquaporin-2, described above) and thirst. Sodium balance is governed primarily by the renin-angiotensin-aldosterone system (RAAS) and by atrial natriuretic peptide. In health, plasma sodium reflects water balance (a sodium abnormality is almost always a water problem), while total body sodium (volume status) reflects sodium balance — a distinction central to interpreting ICU electrolytes.[1]

[1]

The clinical relevance of RAAS activation in critical illness is threefold. First, RAAS blockers (ACE inhibitors, ARBs) can precipitate or worsen shock by removing this defence (loss of angiotensin-II vasoconstriction, loss of efferent arteriolar tone); they should generally be held in acute critical illness. Second, aldosterone-driven potassium excretion explains the hypokalaemia often seen in resuscitated patients. Third, sustained sodium and water retention contributes to the positive fluid balance and oedema of prolonged critical illness — a rationale for later active deresuscitation.[5]

The interaction between ADH and RAAS is the explanation for the near-universal hyponatraemia of the sick ICU patient. When non-osmotic ADH release is APPROPRIATE (true hypovolaemia, shock), the hyponatraemia is a correct physiological response — treat the underlying volume deficit with isotonic saline. When non-osmotic ADH release is INAPPROPRIATE (euvolaemic, as in SIADH from pneumonia, subarachnoid haemorrhage, malignancy, or drugs), the retained water must be managed with fluid restriction, and corrected SLOWLY (no more than 8-10 mmol/L in 24 h) to avoid osmotic demyelination syndrome.[5]

Calcium homeostasis — PTH, vitamin D and calcitonin

The calcium homeostasis

• The PTH (the parathyroid; the - the - the).[1]
• The vitamin D (the - the - the).[1]
• The calcitonin (the thyroid the C cell; the - the - the).[1]

Plasma calcium is maintained in a narrow range (ionised calcium about 1.1-1.3 mmol/L) by three hormones acting on three organs (gut, kidney, bone). About 50% of plasma calcium is ionised (biologically active), 40% is protein-bound (mostly albumin), and 10% is complexed to anions — which is why the corrected calcium formula adds 0.02 mmol/L per g/L of albumin below 40 g/L. Acidosis increases the ionised fraction (displaces calcium from albumin); alkalosis decreases it.[8]

Parathyroid hormone (PTH), from the chief cells of the four parathyroid glands, is the minute-to-minute regulator. It is released when the calcium-sensing receptor (CaSR) on chief cells detects a FALL in ionised calcium, and it RAISES calcium by: (1) BONE — stimulating osteoclasts (indirectly, via RANKL/osteoprotegerin) to resorb bone and release calcium and phosphate; (2) KIDNEY — increasing calcium reabsorption in the distal convoluted tubule (via apical TRPV5 and basolateral Na/Ca exchange) while DECREASING phosphate reabsorption in the proximal tubule (phosphaturia — important because phosphate binds calcium and because high phosphate suppresses 1-alpha-hydroxylase); and (3) GUT — indirectly, by stimulating renal 1-alpha-hydroxylase to activate vitamin D. [1]

Vitamin D (cholecalciferol) is the slower, day-to-day regulator. Synthesised in the skin from 7-dehydrocholesterol under UV-B light (and ingested in the diet), it undergoes 25-hydroxylation in the liver (CYP2R1) to calcifediol (25-OH-D, the storage form measured in blood) and then 1-alpha-hydroxylation in the kidney (CYP27B1, stimulated by PTH and hypophosphataemia, inhibited by FGF-23 and hyperphosphataemia) to the active calcitriol (1,25-(OH)2-D). Calcitriol acts via the vitamin D receptor (nuclear) to increase intestinal absorption of both calcium AND phosphate (by inducing TRPV6 calcium channel and calbindin), and it synergises with PTH on bone.[8]

Calcitonin, from the parafollicular C cells of the thyroid, is the minor, opposing hormone: it LOWERS calcium by inhibiting osteoclast activity. Its physiological role in humans is small (thyroidectomy does not cause hypercalcaemia, and calcitonin excess from medullary thyroid cancer causes only modest hypocalcaemia), but it is therapeutically useful (Paget disease, hypercalcaemia of malignancy).[1]

[1] [1] [1]

Exam-style short-answer questions

[1] [1]

Clinical pearls

Red flags

Key trials and evidence

[1] [1] [1] [1] [1]

Prognosis

The endocrine axes in critical illness behave as biomarkers of severity as much as therapeutic targets. Stress hyperglycaemia: both the mean glucose and its variability, and crucially any episode of hypoglycaemia, are independent predictors of mortality — glycaemic control quality is a measurable marker of ICU performance.[6][3] CIRCI: the need for hydrocortisone in septic shock identifies a sicker subgroup, but within that group hydrocortisone accelerates shock reversal and is catecholamine-sparing; mortality benefit is modest and confined to the most severe (vasopressor-refractory) cases.[1] Sick euthyroid syndrome: the depth and persistence of the low-T3/low-T4 pattern parallel illness severity — a falling T4 is a poor prognostic marker — but it remains an adaptive response that does not benefit from thyroid hormone replacement.[2] Relative vasopressin deficiency: identifying and treating it with low-dose vasopressin is catecholamine-sparing and may benefit less-severe septic shock (VASST subgroup), but it is not a mortality-changing monotherapy.[7] Across all axes, the overarching principle is to SUPPORT the endocrine response where it fails (hydrocortisone in CIRCI, vasopressin in vasoplegic shock, controlled insulin for harmful hyperglycaemia) and to RESIST over-treating the adaptive ones (sick euthyroidism, modest stress hyperglycaemia) — the ICU endocrine skill is judgement, not reflex.[9]

References

1. [1]Marik PE, Pastores SM, Annane D, et al Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine Crit Care Med, 2008.PMID 18496365
2. [2]Adler SM, Wartofsky L The nonthyroidal illness syndrome Endocrinol Metab Clin North Am, 2007.PMID 17673123
3. [3]NICE-SUGAR Study Investigators; Finfer S, Chittock DR, Su SY, et al Intensive versus conventional glucose control in critically ill patients N Engl J Med, 2009.PMID 19318384
4. [4]van den Berghe G, Wouters P, Weekers F, et al Intensive insulin therapy in critically ill patients N Engl J Med, 2001.PMID 11794168
5. [5]Cooper MS, Stewart PM Corticosteroid insufficiency in acutely ill patients N Engl J Med, 2003.PMID 12594318
6. [6]Krinsley JS, Egi M, Kiss A, et al Diabetic status and the relation of the three domains of glycemic control to mortality in critically ill patients: an international multicenter cohort study Crit Care, 2013.PMID 23452622
7. [7]Russell JA, Walley KR, Singer J, et al Vasopressin versus norepinephrine infusion in patients with septic shock N Engl J Med, 2008.PMID 18305265
8. [8]Holick MF Vitamin D deficiency N Engl J Med, 2007.PMID 17634462
9. [9]Dungan KM, Braithwaite SS, Preiser JC Stress hyperglycaemia Lancet, 2009.PMID 19465235